nodes	percent_of_prediction	percent_of_DWPC	metapath
Penicillamine—rheumatoid arthritis—systemic scleroderma	0.723	1	CtDrD
Penicillamine—SLCO1B1—Mycophenolate mofetil—systemic scleroderma	0.118	0.714	CbGbCtD
Penicillamine—SLCO1B1—Methotrexate—systemic scleroderma	0.0473	0.286	CbGbCtD
Penicillamine—Renal failure—Mycophenolic acid—systemic scleroderma	0.000199	0.00178	CcSEcCtD
Penicillamine—Neuropathy peripheral—Mycophenolic acid—systemic scleroderma	0.000198	0.00177	CcSEcCtD
Penicillamine—Vasculitis—Prednisone—systemic scleroderma	0.000198	0.00177	CcSEcCtD
Penicillamine—Agranulocytosis—Leflunomide—systemic scleroderma	0.000198	0.00177	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Pentoxifylline—systemic scleroderma	0.000197	0.00176	CcSEcCtD
Penicillamine—Stomatitis—Mycophenolic acid—systemic scleroderma	0.000197	0.00176	CcSEcCtD
Penicillamine—Dysgeusia—Captopril—systemic scleroderma	0.000197	0.00176	CcSEcCtD
Penicillamine—Arthralgia—Mometasone—systemic scleroderma	0.000195	0.00174	CcSEcCtD
Penicillamine—Pancytopenia—Lisinopril—systemic scleroderma	0.000194	0.00173	CcSEcCtD
Penicillamine—Haematuria—Mycophenolic acid—systemic scleroderma	0.000193	0.00172	CcSEcCtD
Penicillamine—Haemoglobin—Leflunomide—systemic scleroderma	0.000191	0.00171	CcSEcCtD
Penicillamine—Hepatobiliary disease—Mycophenolic acid—systemic scleroderma	0.000191	0.00171	CcSEcCtD
Penicillamine—Haemorrhage—Leflunomide—systemic scleroderma	0.00019	0.0017	CcSEcCtD
Penicillamine—Agranulocytosis—Mycophenolic acid—systemic scleroderma	0.000189	0.00169	CcSEcCtD
Penicillamine—Decreased appetite—Pentoxifylline—systemic scleroderma	0.000188	0.00168	CcSEcCtD
Penicillamine—Urinary tract disorder—Leflunomide—systemic scleroderma	0.000188	0.00168	CcSEcCtD
Penicillamine—Urethral disorder—Leflunomide—systemic scleroderma	0.000186	0.00167	CcSEcCtD
Penicillamine—Anaemia—Captopril—systemic scleroderma	0.000186	0.00166	CcSEcCtD
Penicillamine—Extravasation—Methotrexate—systemic scleroderma	0.000185	0.00165	CcSEcCtD
Penicillamine—Proteinuria—Methotrexate—systemic scleroderma	0.000184	0.00164	CcSEcCtD
Penicillamine—Muscular weakness—Mycophenolate mofetil—systemic scleroderma	0.000183	0.00163	CcSEcCtD
Penicillamine—Haemoglobin—Mycophenolic acid—systemic scleroderma	0.000182	0.00163	CcSEcCtD
Penicillamine—Neuropathy—Prednisone—systemic scleroderma	0.000181	0.00162	CcSEcCtD
Penicillamine—Haemorrhage—Mycophenolic acid—systemic scleroderma	0.000181	0.00162	CcSEcCtD
Penicillamine—Protein urine present—Methotrexate—systemic scleroderma	0.000181	0.00162	CcSEcCtD
Penicillamine—Urinary tract disorder—Mycophenolic acid—systemic scleroderma	0.000179	0.0016	CcSEcCtD
Penicillamine—Renal failure—Lisinopril—systemic scleroderma	0.000179	0.0016	CcSEcCtD
Penicillamine—Asthma—Mycophenolate mofetil—systemic scleroderma	0.000179	0.0016	CcSEcCtD
Penicillamine—Neuropathy peripheral—Lisinopril—systemic scleroderma	0.000178	0.00159	CcSEcCtD
Penicillamine—Alopecia—Azathioprine—systemic scleroderma	0.000178	0.00159	CcSEcCtD
Penicillamine—Anorexia—Mometasone—systemic scleroderma	0.000178	0.00159	CcSEcCtD
Penicillamine—Urethral disorder—Mycophenolic acid—systemic scleroderma	0.000178	0.00159	CcSEcCtD
Penicillamine—Pancreatitis—Mycophenolate mofetil—systemic scleroderma	0.000175	0.00157	CcSEcCtD
Penicillamine—Glossitis—Methotrexate—systemic scleroderma	0.000175	0.00157	CcSEcCtD
Penicillamine—Haematuria—Lisinopril—systemic scleroderma	0.000174	0.00155	CcSEcCtD
Penicillamine—Hepatobiliary disease—Lisinopril—systemic scleroderma	0.000172	0.00154	CcSEcCtD
Penicillamine—Urticaria—Pentoxifylline—systemic scleroderma	0.000172	0.00154	CcSEcCtD
Penicillamine—Arthralgia—Captopril—systemic scleroderma	0.000171	0.00153	CcSEcCtD
Penicillamine—Body temperature increased—Pentoxifylline—systemic scleroderma	0.000171	0.00153	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Mometasone—systemic scleroderma	0.00017	0.00152	CcSEcCtD
Penicillamine—Pancytopenia—Mycophenolate mofetil—systemic scleroderma	0.00017	0.00152	CcSEcCtD
Penicillamine—Agranulocytosis—Lisinopril—systemic scleroderma	0.00017	0.00152	CcSEcCtD
Penicillamine—Tinnitus—Mycophenolic acid—systemic scleroderma	0.000169	0.00151	CcSEcCtD
Penicillamine—Alopecia—Leflunomide—systemic scleroderma	0.000168	0.0015	CcSEcCtD
Penicillamine—Mental disorder—Leflunomide—systemic scleroderma	0.000167	0.00149	CcSEcCtD
Penicillamine—Vasculitis—Methotrexate—systemic scleroderma	0.000165	0.00148	CcSEcCtD
Penicillamine—Angiopathy—Mycophenolic acid—systemic scleroderma	0.000165	0.00147	CcSEcCtD
Penicillamine—Decreased appetite—Mometasone—systemic scleroderma	0.000162	0.00145	CcSEcCtD
Penicillamine—Dysgeusia—Leflunomide—systemic scleroderma	0.000162	0.00145	CcSEcCtD
Penicillamine—Thrombophlebitis—Prednisone—systemic scleroderma	0.000162	0.00145	CcSEcCtD
Penicillamine—Anaemia—Azathioprine—systemic scleroderma	0.000162	0.00145	CcSEcCtD
Penicillamine—Urinary tract disorder—Lisinopril—systemic scleroderma	0.000161	0.00144	CcSEcCtD
Penicillamine—Thrombocytopenia—Captopril—systemic scleroderma	0.000161	0.00143	CcSEcCtD
Penicillamine—Alopecia—Mycophenolic acid—systemic scleroderma	0.00016	0.00143	CcSEcCtD
Penicillamine—Urethral disorder—Lisinopril—systemic scleroderma	0.00016	0.00143	CcSEcCtD
Penicillamine—Hypersensitivity—Pentoxifylline—systemic scleroderma	0.000159	0.00142	CcSEcCtD
Penicillamine—Mental disorder—Mycophenolic acid—systemic scleroderma	0.000159	0.00142	CcSEcCtD
Penicillamine—Leukopenia—Azathioprine—systemic scleroderma	0.000157	0.0014	CcSEcCtD
Penicillamine—Renal failure—Mycophenolate mofetil—systemic scleroderma	0.000157	0.0014	CcSEcCtD
Penicillamine—Neuropathy peripheral—Mycophenolate mofetil—systemic scleroderma	0.000156	0.0014	CcSEcCtD
Penicillamine—Anorexia—Captopril—systemic scleroderma	0.000156	0.0014	CcSEcCtD
Penicillamine—Stomatitis—Mycophenolate mofetil—systemic scleroderma	0.000155	0.00139	CcSEcCtD
Penicillamine—Anaemia—Leflunomide—systemic scleroderma	0.000153	0.00137	CcSEcCtD
Penicillamine—Injury—Prednisone—systemic scleroderma	0.000153	0.00136	CcSEcCtD
Penicillamine—Tinnitus—Lisinopril—systemic scleroderma	0.000152	0.00136	CcSEcCtD
Penicillamine—Haematuria—Mycophenolate mofetil—systemic scleroderma	0.000152	0.00136	CcSEcCtD
Penicillamine—Aplastic anaemia—Methotrexate—systemic scleroderma	0.000152	0.00136	CcSEcCtD
Penicillamine—Hepatobiliary disease—Mycophenolate mofetil—systemic scleroderma	0.000151	0.00135	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Captopril—systemic scleroderma	0.000149	0.00133	CcSEcCtD
Penicillamine—Arthralgia—Azathioprine—systemic scleroderma	0.000149	0.00133	CcSEcCtD
Penicillamine—Agranulocytosis—Mycophenolate mofetil—systemic scleroderma	0.000149	0.00133	CcSEcCtD
Penicillamine—Angiopathy—Lisinopril—systemic scleroderma	0.000148	0.00133	CcSEcCtD
Penicillamine—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—systemic scleroderma	0.000148	0.00132	CcSEcCtD
Penicillamine—Leukopenia—Leflunomide—systemic scleroderma	0.000148	0.00132	CcSEcCtD
Penicillamine—Diarrhoea—Pentoxifylline—systemic scleroderma	0.000148	0.00132	CcSEcCtD
Penicillamine—Body temperature increased—Mometasone—systemic scleroderma	0.000148	0.00132	CcSEcCtD
Penicillamine—Mouth ulceration—Methotrexate—systemic scleroderma	0.000146	0.00131	CcSEcCtD
Penicillamine—Anaemia—Mycophenolic acid—systemic scleroderma	0.000146	0.0013	CcSEcCtD
Penicillamine—Agitation—Mycophenolic acid—systemic scleroderma	0.000145	0.0013	CcSEcCtD
Penicillamine—Alopecia—Lisinopril—systemic scleroderma	0.000144	0.00129	CcSEcCtD
Penicillamine—Haemoglobin—Mycophenolate mofetil—systemic scleroderma	0.000144	0.00129	CcSEcCtD
Penicillamine—Haemorrhage—Mycophenolate mofetil—systemic scleroderma	0.000143	0.00128	CcSEcCtD
Penicillamine—Mental disorder—Lisinopril—systemic scleroderma	0.000143	0.00128	CcSEcCtD
Penicillamine—Decreased appetite—Captopril—systemic scleroderma	0.000143	0.00127	CcSEcCtD
Penicillamine—Urinary tract disorder—Mycophenolate mofetil—systemic scleroderma	0.000141	0.00126	CcSEcCtD
Penicillamine—Leukopenia—Mycophenolic acid—systemic scleroderma	0.000141	0.00126	CcSEcCtD
Penicillamine—Arthralgia—Leflunomide—systemic scleroderma	0.000141	0.00126	CcSEcCtD
Penicillamine—Anxiety—Leflunomide—systemic scleroderma	0.00014	0.00126	CcSEcCtD
Penicillamine—Urethral disorder—Mycophenolate mofetil—systemic scleroderma	0.00014	0.00125	CcSEcCtD
Penicillamine—Thrombocytopenia—Azathioprine—systemic scleroderma	0.00014	0.00125	CcSEcCtD
Penicillamine—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.00014	0.00125	CcSEcCtD
Penicillamine—Dysgeusia—Lisinopril—systemic scleroderma	0.000139	0.00125	CcSEcCtD
Penicillamine—Skin disorder—Azathioprine—systemic scleroderma	0.000139	0.00124	CcSEcCtD
Penicillamine—Vomiting—Pentoxifylline—systemic scleroderma	0.000138	0.00123	CcSEcCtD
Penicillamine—Lymphadenopathy—Methotrexate—systemic scleroderma	0.000137	0.00123	CcSEcCtD
Penicillamine—Rash—Pentoxifylline—systemic scleroderma	0.000136	0.00122	CcSEcCtD
Penicillamine—Dermatitis—Pentoxifylline—systemic scleroderma	0.000136	0.00122	CcSEcCtD
Penicillamine—Thrombophlebitis—Methotrexate—systemic scleroderma	0.000135	0.00121	CcSEcCtD
Penicillamine—Arthralgia—Mycophenolic acid—systemic scleroderma	0.000134	0.0012	CcSEcCtD
Penicillamine—Anxiety—Mycophenolic acid—systemic scleroderma	0.000134	0.0012	CcSEcCtD
Penicillamine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.000134	0.00119	CcSEcCtD
Penicillamine—Tinnitus—Mycophenolate mofetil—systemic scleroderma	0.000133	0.00119	CcSEcCtD
Penicillamine—Thrombocytopenia—Leflunomide—systemic scleroderma	0.000132	0.00118	CcSEcCtD
Penicillamine—Anaemia—Lisinopril—systemic scleroderma	0.000131	0.00118	CcSEcCtD
Penicillamine—Skin disorder—Leflunomide—systemic scleroderma	0.000131	0.00117	CcSEcCtD
Penicillamine—Hepatic failure—Methotrexate—systemic scleroderma	0.00013	0.00117	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	0.00013	0.00117	CcSEcCtD
Penicillamine—Angiopathy—Mycophenolate mofetil—systemic scleroderma	0.00013	0.00116	CcSEcCtD
Penicillamine—Body temperature increased—Captopril—systemic scleroderma	0.00013	0.00116	CcSEcCtD
Penicillamine—Anorexia—Leflunomide—systemic scleroderma	0.000129	0.00115	CcSEcCtD
Penicillamine—Nausea—Pentoxifylline—systemic scleroderma	0.000128	0.00115	CcSEcCtD
Penicillamine—Diarrhoea—Mometasone—systemic scleroderma	0.000128	0.00114	CcSEcCtD
Penicillamine—Leukopenia—Lisinopril—systemic scleroderma	0.000127	0.00114	CcSEcCtD
Penicillamine—Alopecia—Mycophenolate mofetil—systemic scleroderma	0.000127	0.00113	CcSEcCtD
Penicillamine—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.000126	0.00113	CcSEcCtD
Penicillamine—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.000125	0.00112	CcSEcCtD
Penicillamine—Skin disorder—Mycophenolic acid—systemic scleroderma	0.000125	0.00112	CcSEcCtD
Penicillamine—Dermatitis exfoliative—Methotrexate—systemic scleroderma	0.000124	0.00111	CcSEcCtD
Penicillamine—Muscular weakness—Prednisone—systemic scleroderma	0.000124	0.00111	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.000123	0.0011	CcSEcCtD
Penicillamine—Anorexia—Mycophenolic acid—systemic scleroderma	0.000123	0.0011	CcSEcCtD
Penicillamine—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.000122	0.00109	CcSEcCtD
Penicillamine—Arthralgia—Lisinopril—systemic scleroderma	0.000121	0.00108	CcSEcCtD
Penicillamine—Anxiety—Lisinopril—systemic scleroderma	0.000121	0.00108	CcSEcCtD
Penicillamine—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.00012	0.00107	CcSEcCtD
Penicillamine—Pancreatitis—Prednisone—systemic scleroderma	0.000119	0.00106	CcSEcCtD
Penicillamine—Vomiting—Mometasone—systemic scleroderma	0.000119	0.00106	CcSEcCtD
Penicillamine—Rash—Mometasone—systemic scleroderma	0.000118	0.00105	CcSEcCtD
Penicillamine—Dermatitis—Mometasone—systemic scleroderma	0.000118	0.00105	CcSEcCtD
Penicillamine—Decreased appetite—Leflunomide—systemic scleroderma	0.000117	0.00105	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000117	0.00105	CcSEcCtD
Penicillamine—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000115	0.00103	CcSEcCtD
Penicillamine—Agitation—Mycophenolate mofetil—systemic scleroderma	0.000115	0.00102	CcSEcCtD
Penicillamine—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000114	0.00102	CcSEcCtD
Penicillamine—Body temperature increased—Azathioprine—systemic scleroderma	0.000113	0.00101	CcSEcCtD
Penicillamine—Skin disorder—Lisinopril—systemic scleroderma	0.000113	0.00101	CcSEcCtD
Penicillamine—Diarrhoea—Captopril—systemic scleroderma	0.000112	0.001	CcSEcCtD
Penicillamine—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000112	0.001	CcSEcCtD
Penicillamine—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000112	0.000997	CcSEcCtD
Penicillamine—Nausea—Mometasone—systemic scleroderma	0.000111	0.000991	CcSEcCtD
Penicillamine—Anorexia—Lisinopril—systemic scleroderma	0.000111	0.000989	CcSEcCtD
Penicillamine—Urticaria—Leflunomide—systemic scleroderma	0.000107	0.000959	CcSEcCtD
Penicillamine—Body temperature increased—Leflunomide—systemic scleroderma	0.000107	0.000955	CcSEcCtD
Penicillamine—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000106	0.000948	CcSEcCtD
Penicillamine—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000106	0.000947	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000106	0.000945	CcSEcCtD
Penicillamine—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000106	0.000945	CcSEcCtD
Penicillamine—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000106	0.000944	CcSEcCtD
Penicillamine—Hypersensitivity—Azathioprine—systemic scleroderma	0.000105	0.000942	CcSEcCtD
Penicillamine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000105	0.000942	CcSEcCtD
Penicillamine—Vomiting—Captopril—systemic scleroderma	0.000104	0.000932	CcSEcCtD
Penicillamine—Rash—Captopril—systemic scleroderma	0.000103	0.000924	CcSEcCtD
Penicillamine—Dermatitis—Captopril—systemic scleroderma	0.000103	0.000923	CcSEcCtD
Penicillamine—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000102	0.000911	CcSEcCtD
Penicillamine—Asthma—Methotrexate—systemic scleroderma	0.000101	0.000906	CcSEcCtD
Penicillamine—Decreased appetite—Lisinopril—systemic scleroderma	0.000101	0.000902	CcSEcCtD
Penicillamine—Eosinophilia—Methotrexate—systemic scleroderma	0.0001	0.000897	CcSEcCtD
Penicillamine—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	9.96e-05	0.00089	CcSEcCtD
Penicillamine—Hypersensitivity—Leflunomide—systemic scleroderma	9.95e-05	0.00089	CcSEcCtD
Penicillamine—Pancreatitis—Methotrexate—systemic scleroderma	9.94e-05	0.000888	CcSEcCtD
Penicillamine—Skin disorder—Mycophenolate mofetil—systemic scleroderma	9.88e-05	0.000883	CcSEcCtD
Penicillamine—Diarrhoea—Azathioprine—systemic scleroderma	9.79e-05	0.000875	CcSEcCtD
Penicillamine—Haemoglobin—Prednisone—systemic scleroderma	9.75e-05	0.000872	CcSEcCtD
Penicillamine—Nausea—Captopril—systemic scleroderma	9.74e-05	0.00087	CcSEcCtD
Penicillamine—Haemorrhage—Prednisone—systemic scleroderma	9.71e-05	0.000867	CcSEcCtD
Penicillamine—Anorexia—Mycophenolate mofetil—systemic scleroderma	9.7e-05	0.000867	CcSEcCtD
Penicillamine—Pancytopenia—Methotrexate—systemic scleroderma	9.62e-05	0.00086	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	9.27e-05	0.000828	CcSEcCtD
Penicillamine—Diarrhoea—Leflunomide—systemic scleroderma	9.24e-05	0.000826	CcSEcCtD
Penicillamine—Urticaria—Lisinopril—systemic scleroderma	9.22e-05	0.000824	CcSEcCtD
Penicillamine—Body temperature increased—Lisinopril—systemic scleroderma	9.18e-05	0.00082	CcSEcCtD
Penicillamine—Vomiting—Azathioprine—systemic scleroderma	9.1e-05	0.000813	CcSEcCtD
Penicillamine—Rash—Azathioprine—systemic scleroderma	9.02e-05	0.000806	CcSEcCtD
Penicillamine—Dermatitis—Azathioprine—systemic scleroderma	9.01e-05	0.000806	CcSEcCtD
Penicillamine—Renal failure—Methotrexate—systemic scleroderma	8.88e-05	0.000794	CcSEcCtD
Penicillamine—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	8.84e-05	0.00079	CcSEcCtD
Penicillamine—Diarrhoea—Mycophenolic acid—systemic scleroderma	8.82e-05	0.000788	CcSEcCtD
Penicillamine—Stomatitis—Methotrexate—systemic scleroderma	8.81e-05	0.000787	CcSEcCtD
Penicillamine—Angiopathy—Prednisone—systemic scleroderma	8.81e-05	0.000787	CcSEcCtD
Penicillamine—Haematuria—Methotrexate—systemic scleroderma	8.61e-05	0.00077	CcSEcCtD
Penicillamine—Vomiting—Leflunomide—systemic scleroderma	8.59e-05	0.000768	CcSEcCtD
Penicillamine—Alopecia—Prednisone—systemic scleroderma	8.58e-05	0.000767	CcSEcCtD
Penicillamine—Hypersensitivity—Lisinopril—systemic scleroderma	8.55e-05	0.000765	CcSEcCtD
Penicillamine—Hepatobiliary disease—Methotrexate—systemic scleroderma	8.55e-05	0.000764	CcSEcCtD
Penicillamine—Rash—Leflunomide—systemic scleroderma	8.52e-05	0.000761	CcSEcCtD
Penicillamine—Dermatitis—Leflunomide—systemic scleroderma	8.51e-05	0.000761	CcSEcCtD
Penicillamine—Mental disorder—Prednisone—systemic scleroderma	8.5e-05	0.00076	CcSEcCtD
Penicillamine—Nausea—Azathioprine—systemic scleroderma	8.5e-05	0.00076	CcSEcCtD
Penicillamine—Agranulocytosis—Methotrexate—systemic scleroderma	8.43e-05	0.000754	CcSEcCtD
Penicillamine—Vomiting—Mycophenolic acid—systemic scleroderma	8.2e-05	0.000732	CcSEcCtD
Penicillamine—Haemoglobin—Methotrexate—systemic scleroderma	8.15e-05	0.000729	CcSEcCtD
Penicillamine—Rash—Mycophenolic acid—systemic scleroderma	8.13e-05	0.000726	CcSEcCtD
Penicillamine—Dermatitis—Mycophenolic acid—systemic scleroderma	8.12e-05	0.000726	CcSEcCtD
Penicillamine—Haemorrhage—Methotrexate—systemic scleroderma	8.11e-05	0.000725	CcSEcCtD
Penicillamine—Urticaria—Mycophenolate mofetil—systemic scleroderma	8.08e-05	0.000722	CcSEcCtD
Penicillamine—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	8.04e-05	0.000719	CcSEcCtD
Penicillamine—Nausea—Leflunomide—systemic scleroderma	8.03e-05	0.000717	CcSEcCtD
Penicillamine—Urinary tract disorder—Methotrexate—systemic scleroderma	8.01e-05	0.000716	CcSEcCtD
Penicillamine—Urethral disorder—Methotrexate—systemic scleroderma	7.95e-05	0.000711	CcSEcCtD
Penicillamine—Diarrhoea—Lisinopril—systemic scleroderma	7.94e-05	0.00071	CcSEcCtD
Penicillamine—Anaemia—Prednisone—systemic scleroderma	7.81e-05	0.000698	CcSEcCtD
Penicillamine—Agitation—Prednisone—systemic scleroderma	7.76e-05	0.000694	CcSEcCtD
Penicillamine—Nausea—Mycophenolic acid—systemic scleroderma	7.66e-05	0.000684	CcSEcCtD
Penicillamine—Tinnitus—Methotrexate—systemic scleroderma	7.56e-05	0.000676	CcSEcCtD
Penicillamine—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	7.49e-05	0.00067	CcSEcCtD
Penicillamine—Vomiting—Lisinopril—systemic scleroderma	7.38e-05	0.00066	CcSEcCtD
Penicillamine—Angiopathy—Methotrexate—systemic scleroderma	7.36e-05	0.000658	CcSEcCtD
Penicillamine—Rash—Lisinopril—systemic scleroderma	7.32e-05	0.000654	CcSEcCtD
Penicillamine—Dermatitis—Lisinopril—systemic scleroderma	7.31e-05	0.000654	CcSEcCtD
Penicillamine—Arthralgia—Prednisone—systemic scleroderma	7.19e-05	0.000643	CcSEcCtD
Penicillamine—Anxiety—Prednisone—systemic scleroderma	7.17e-05	0.000641	CcSEcCtD
Penicillamine—Alopecia—Methotrexate—systemic scleroderma	7.17e-05	0.000641	CcSEcCtD
Penicillamine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	7.14e-05	0.000638	CcSEcCtD
Penicillamine—Mental disorder—Methotrexate—systemic scleroderma	7.11e-05	0.000635	CcSEcCtD
Penicillamine—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	6.96e-05	0.000622	CcSEcCtD
Penicillamine—Dysgeusia—Methotrexate—systemic scleroderma	6.91e-05	0.000618	CcSEcCtD
Penicillamine—Nausea—Lisinopril—systemic scleroderma	6.9e-05	0.000616	CcSEcCtD
Penicillamine—Skin disorder—Prednisone—systemic scleroderma	6.7e-05	0.000599	CcSEcCtD
Penicillamine—Anorexia—Prednisone—systemic scleroderma	6.57e-05	0.000587	CcSEcCtD
Penicillamine—Anaemia—Methotrexate—systemic scleroderma	6.53e-05	0.000583	CcSEcCtD
Penicillamine—Vomiting—Mycophenolate mofetil—systemic scleroderma	6.47e-05	0.000578	CcSEcCtD
Penicillamine—Rash—Mycophenolate mofetil—systemic scleroderma	6.41e-05	0.000573	CcSEcCtD
Penicillamine—Dermatitis—Mycophenolate mofetil—systemic scleroderma	6.41e-05	0.000573	CcSEcCtD
Penicillamine—Leukopenia—Methotrexate—systemic scleroderma	6.32e-05	0.000565	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Prednisone—systemic scleroderma	6.28e-05	0.000561	CcSEcCtD
Penicillamine—Nausea—Mycophenolate mofetil—systemic scleroderma	6.04e-05	0.00054	CcSEcCtD
Penicillamine—Arthralgia—Methotrexate—systemic scleroderma	6.01e-05	0.000537	CcSEcCtD
Penicillamine—Decreased appetite—Prednisone—systemic scleroderma	5.99e-05	0.000536	CcSEcCtD
Penicillamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	5.97e-05	0.000534	CcSEcCtD
Penicillamine—Thrombocytopenia—Methotrexate—systemic scleroderma	5.64e-05	0.000504	CcSEcCtD
Penicillamine—Skin disorder—Methotrexate—systemic scleroderma	5.6e-05	0.0005	CcSEcCtD
Penicillamine—Anorexia—Methotrexate—systemic scleroderma	5.49e-05	0.000491	CcSEcCtD
Penicillamine—Urticaria—Prednisone—systemic scleroderma	5.48e-05	0.00049	CcSEcCtD
Penicillamine—Body temperature increased—Prednisone—systemic scleroderma	5.45e-05	0.000487	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	5.25e-05	0.000469	CcSEcCtD
Penicillamine—Hypersensitivity—Prednisone—systemic scleroderma	5.08e-05	0.000454	CcSEcCtD
Penicillamine—Decreased appetite—Methotrexate—systemic scleroderma	5.01e-05	0.000448	CcSEcCtD
Penicillamine—Diarrhoea—Prednisone—systemic scleroderma	4.72e-05	0.000422	CcSEcCtD
Penicillamine—Urticaria—Methotrexate—systemic scleroderma	4.58e-05	0.000409	CcSEcCtD
Penicillamine—Body temperature increased—Methotrexate—systemic scleroderma	4.56e-05	0.000407	CcSEcCtD
Penicillamine—Vomiting—Prednisone—systemic scleroderma	4.38e-05	0.000392	CcSEcCtD
Penicillamine—Rash—Prednisone—systemic scleroderma	4.35e-05	0.000389	CcSEcCtD
Penicillamine—Dermatitis—Prednisone—systemic scleroderma	4.34e-05	0.000388	CcSEcCtD
Penicillamine—Hypersensitivity—Methotrexate—systemic scleroderma	4.25e-05	0.000379	CcSEcCtD
Penicillamine—Nausea—Prednisone—systemic scleroderma	4.1e-05	0.000366	CcSEcCtD
Penicillamine—Diarrhoea—Methotrexate—systemic scleroderma	3.94e-05	0.000352	CcSEcCtD
Penicillamine—Vomiting—Methotrexate—systemic scleroderma	3.66e-05	0.000327	CcSEcCtD
Penicillamine—Rash—Methotrexate—systemic scleroderma	3.63e-05	0.000325	CcSEcCtD
Penicillamine—Dermatitis—Methotrexate—systemic scleroderma	3.63e-05	0.000324	CcSEcCtD
Penicillamine—Nausea—Methotrexate—systemic scleroderma	3.42e-05	0.000306	CcSEcCtD
